Aerovate Therapeutics announced on October 30, 2024, a merger agreement with Jade Biosciences, which includes potential litigation from stockholders regarding disclosures related to the merger. The merger involves a valuation of Aerovate at $10 million and a special cash dividend of 100% of its net cash to stockholders.